We would like to thank the authors for their paper "Comparison of Commercial RT-PCR Diagnostic Kits for COVID-19" \[[@bib0005]\], published in the Journal of Clinical Virology, which found all of the RT-PCR kits reviewed were suitable for SARS-COV-2 RNA detection.
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We have reviewed the paper and were surprised by the findings. In kind, we would like to alert you to some of the shortcomings in the provided information, and discuss contravening evidence, all of which call into question the reported results:

1. Comparison methodology {#sec0005}
=========================

Comparing diagnostics tests with archive samples is an inherently difficult process. This is due to the number of confounding factors that can influence the reliability of results (patient sampling, extraction efficiency variability, storage of eluates etc.). A more controlled method for comparing diagnostic tests is the usage of single-use external quality assessment (EQA) panels.

We appreciate the authors will have strove to minimise the impact of confounding factors, however the measures that were applied are unclear. For example, were the archive samples stored as aliquots to control the number of freeze-thaw cycles across the testing programme? How long were the samples stored between tests? Without answers to such questions, the reader cannot guarantee the study design conferred a sufficient level of inter-assay equivalency.

For measuring the presence of confounding factors, process controls are extremely helpful. All qPCR diagnostic assays are provided with process controls, however no data regarding any of the process controls is provided. Our process control is an RNA template spiked into the extraction during the lysis stage. The authors do not report whether this process control amplified in the samples that our assay 'failed' to detect. Therefore, the reader cannot determine whether any of the 'negatives' reported are an appropriate determination or the result of other factors affecting the PCR.

Confounding factors can have a significant impact when detecting low copy numbers with qPCR. Could the presence of factors external to the qPCR explain why the authors report that the commercial assay which demonstrated the best analytical sensitivity (Altona Diagnostics) also produced the worst positive sample detection rate? Without further clarity on the control measures put in place during the study, we cannot know. Therefore, the comparative limits of detection (LODs) reported within the article should not be taken as a verified claim.

2. Contravening evidence {#sec0010}
========================

In response to the COVID-19 pandemic the Foundation for Innovative New Diagnostics (FIND) made a public expression of interest (EOI), inviting in vitro diagnostic (IVD) manufacturers to apply to take part in a clinical performance evaluation of COVID-19 diagnostic tests. Having submitted an application that was accepted, our test was included in these evaluations conducted at the University Hospitals of Geneva (HUG).

This study used clinical isolates from Switzerland for the LOD, and archive samples from individuals suspected to have COVID-19 for the clinical performance evaluation. FIND report that our Coronavirus COVID-19 genesig® Real-Time PCR assay exhibits 100 % clinical sensitivity (correctly identifying 50 positive samples) and 100 % clinical specificity (correctly identifying 100 negative samples) \[[@bib0010]\]. This stands in stark contrast to this data reported by the authors which states that our assay only detected 10 out 13 positives. Additionally, in FIND's comparative LOD study our assay achieved the highest LOD banding (1--10 copies/reaction) and outperformed the RdRp assay of a competitor (KH Medical), which again stands in contrast to the authors' findings \[[@bib0010]\].

We believe this is strong evidence that the Coronavirus COVID-19 genesig® Real-Time PCR assay is a state-of-the art diagnostic test, and that the data published in the authors' manuscript is not reproducible. It is therefore incumbent on this journal to address the discrepancy.

FIND is a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation. Their evaluation data comparing commercial COVID-19 assays is available here: <https://www.finddx.org/covid-19/sarscov2-eval-molecular/molecular-eval-results/>.

We look forward to the authors' response to the concerns we have raised and request the journal investigate the methodology and results of this manuscript and consider issuing an expression of concern.
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